Woojin B&G Receives Clinical Trial Approval for 'Pig Circo-Mycoplasma Combined Preventive Vaccine'

[Asia Economy Reporter Hyunseok Yoo] Woojin BNJ announced on the 16th that it has received final approval from the Animal and Plant Quarantine Agency for the clinical trial plan of the "Porcine Circovirus and Mycoplasma Combined Preventive Vaccine (Immunis® DMVaccine)."

"Immunis® DMVaccine" is a vaccine that simultaneously prevents "Porcine Circovirus Type 2 (PCV-2)" and "Mycoplasma," which affect productivity decline in pig farms. Woojin BNJ's vaccine team recently developed this vaccine using vaccine strains of "Circovirus" isolated domestically and "Mycoplasma" isolated from the lungs of pigs showing mycoplasma pneumonia lesions at domestic slaughterhouses by Seoul National University and Wonkwang University.

Through its own experiments evaluating safety and efficacy, Woojin BNJ confirmed that the vaccinated group showed significantly lower blood antigen levels and pneumonia lesions compared to the unvaccinated control group.

"Circovirus" and "Mycoplasma" are representative pathogens that are endemic in pig farms and infect the respiratory tracts of young pigs, causing problems. These pathogens often cause mixed infections with other respiratory viruses and bacteria, leading to ▲growth retardation due to respiratory symptoms ▲reduced feed efficiency, and in severe cases, increased mortality rates, resulting in losses to farms.

A Woojin BNJ official stated, "We will conduct efficacy and safety tests of DMVaccine according to the approved clinical trial plan," and added, "We also plan to verify the cross-protection against the problematic domestic circovirus genotypes 2a, 2b, and 2d, as well as the protective ability against Mycoplasma in actual farm conditions."